| Canine parvovirus disease and canine distemper are two main infectious diseases that endanger the dog industry.Now the immunization fails and the clinical cure rate is low.Interferon(IFN)is a great anti-virus,anti-tumor and immunomodulatory cytokine.It has been widely used in treating animal diseases.However,canine research is not sufficient,and it is mostly limited to preparation,detection methods and biological effects.The evaluation of the price is rarely reported in clinical applications.We used 6~8-week-old healthy beagle dogs as the research object with using the yeast Pichia eukaryotes and obtained recombinant interferon was purified and treated with different doses of conventional immunized dogs.Canine parvovirus antibody and canine distemper virus antibody were determined by ELISA at 0 d,3 d,7 d,and 14 d after vaccine immunization to observe the effect of recombinant interferon in dog immunity on canine immunity,to extract canine parvovirus with canine feces from parvovirus and to use different doses of canine recombinant interferon to treat dogs in groups and to cooperate with support and symptomatic treatment by means of clinical examination and blood physiological and biochemical indicators to observe the therapeutic effect,which provides a theoretical basis for the prevention and treatment of canine parvovirus and canine distemper virus.The results suggested that the high-dose canine recombinant interferon plus vaccine group(group III)had the lowest antibody serum canine parvovirus(160.75±2.75)ng/mL and(196.50±2.64)ng/mL at the 14 th day after the first,second and third exemptions.(256.00±6.68)ng/mL;medium-dose dog recombinant interferon plus vaccine group(IV group)up to(214.00±2.58)ng/mL,(315.25±1.70)ng/mL,(462.25±3.77)ng/mL;low dose canine recombinant interferon plus vaccine(group V)up to(228.25±2.75)ng/mL,(363.25±2.21)ng/mL,(541.75±2.62)ng/mL;the higher in the saline group(group I)(160.50±2.08)ng/mL,(64.75±1.70)ng/mL,(48±1.83)ng/mL(P<0.01).After third exemption,each of Interferon antibodies were significantly lower than the vaccine(group II)(676.5±2.38)ng/mL(P<0.01).Compared with group III,IV and V,serum antibody levels in group V canine parvovirus were significantly higher than those in group III and IV.End of immunization changes in the levels of canine venom antibody and canine parvovirus serum antibody levels were consistent.It can be seen that the vaccine group has the highest level of immune antibodies and canine recombinant interferon has an inhibitory effect on the vaccine.For the replication of parvovirus canine group treatment results successfully,the red blood cell content of the 7 d high-dose treatment group + symptomatic and supportive treatment group(VI group)was significantly higher than that of the middle-dose treatment group + symptomatic and supportive treatment group(V group)(P<0.05),which is significantly higher than symptomatic and supportive treatment groups(Group III)(P<0.01).The blood platelet content in group VI was significantly higher than that in group III(P<0.01).There was no significant difference in leukocyte content between groups(P>0.05).The serum CK level in V and VI groups was significantly lower than that in group III(P<0.05).The difference of ALT content was not significant(P>0.05).There was no significant difference in serum AST levels between the low-,medium-,and high-dose treatment groups and the symptomatic and supportive treatment groups(P>0.05),but they were lower than those of the symptomatic and supportive treatment groups(Group III)(P<0.05).In Group III,the mortality rate was 40%,and the cure rate was 20%;In Group IV,the mortality rate was 20%,and the cure rate was 80%.In the IV and V groups,the mortality rate was 0% and the cure rate was 100%.It can be seen that high dose canine recombinant interferon has the best clinical efficacy. |
PDF Full Text Request